September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Joakim Nordanstig: SWEDEPAD Data Show Early Risk Of Limb Loss With Paclitaxel-Coated Devices

Joakim Nordanstig/LinkedIn

Apr 24, 2026, 13:34

Joakim Nordanstig: SWEDEPAD Data Show Early Risk Of Limb Loss With Paclitaxel-Coated Devices

Joakim Nordanstig, President at Swedish Society for Vascular Surgery (SSVS), shared a post on LinkedIn:

”Very honoured to have been invited to the absolutely amazing Charing Cross Vascular and Endovascular Consensus Meeting in London this week.

Today, we provided data updates from the SWEDEPAD trials, including a detailed subgroup analysis in Rutherford 5-6 patients from SWEDEPAD 1, demonstrating an increased early risk for limb loss in patients treated with paclitaxel-coated devices compared to uncoated devices.

This observation may explain to overall neutral results in terms of major amputation rates (the primary endpoint) previously reported from SWEDEPAD 1. My colleague (dr Mårten Falkenberg) also presented important cause-specific mortality rate data from both SWEDEPAD 1 and 2 in an effort to better understand the late mortality signal noted with paclitaxel-coated devices.

We also presented vessel segment-specific data, showing that the previously reported reduced TVR rates with paclitaxel-coated devices was mainly driven by interventions in the femoropopliteal segment, whereas results were neutral infrapopliteally.”

Joakim Nordanstig: SWEDEPAD Data Show Early Risk Of Limb Loss With Paclitaxel-Coated Devices